Axsome Therapeutics (AXSM) EBITDA Margin (2022 - 2026)
Axsome Therapeutics (AXSM) reported EBITDA Margin of 33.14% for Q1 2026, up 1378.0% on a YoY basis from 2.24% in Q1 2025, and down 140.93% sequentially from 13.75% in Q4 2025.
Axsome Therapeutics (AXSM) EBITDA Margin (2022 - 2026) Analysis & Trends
Axsome Therapeutics (AXSM) has 5 years of EBITDA Margin data on file, last reported at 33.14% in Q1 2026.
- For the quarter ending Q1 2026, EBITDA Margin rose 1378.0% year-over-year to 33.14%; the trailing twelve-month figure through Mar 2026 stood at 24.45% (up 6166.0% YoY), and the FY2025 full-year result was 26.12%, up 4662.0% from the prior year.
- EBITDA Margin fell to 33.14% in Q1 2026, from 13.75% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 6.74% in Q1 2023 to a low of 14523.4% in Q4 2024.
- A 5-year average of 1015.03% and a median of 89.62% in 2024 frame the typical range for EBITDA Margin.
- Across the five-year window, EBITDA Margin sank 1438601 bps in 2024 and soared 1450965 bps in 2025, its largest moves.
- Tracing AXSM's EBITDA Margin over 5 years: stood at 245.86% in 2022, then soared by 44 bps to 137.39% in 2023, then plunged by 10471 bps to 14523.4% in 2024, then jumped by 100 bps to 13.75% in 2025, then slumped by 141 bps to 33.14% in 2026.
- Business Quant data shows AXSM's EBITDA Margin at 33.14% in Q1 2026, 13.75% in Q4 2025, and 26.97% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Axsome Therapeutics | 12.37 Bn | 12.06 Bn | 176.48 Mn | -33.14% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -33.14% |
| Dec 31, 2025 | -13.75% |
| Sep 30, 2025 | -26.97% |
| Jun 30, 2025 | -24.47% |
| Mar 31, 2025 | -46.91% |
| Dec 31, 2024 | -14,523.40% |
| Sep 30, 2024 | -59.78% |
| Jun 30, 2024 | -89.54% |
| Mar 31, 2024 | -89.70% |
| Dec 31, 2023 | -137.39% |
| Sep 30, 2023 | -107.49% |
| Jun 30, 2023 | -139.31% |
| Mar 31, 2023 | -6.74% |
| Dec 31, 2022 | -245.86% |
| Sep 30, 2022 | -251.76% |
| Jun 30, 2022 | -444.23% |